{"analyses":[{"ciLowerLimit":"0.548","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.053","estimateComment":"HR was calculated based on the Cox Proportional hazards model stratified by ECOG PS, race group, and brain metastases. Assuming proportional hazards, a hazard ratio (less than)\\<1 indicates a reduction in hazard rate in favor of crizotinib.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0489","pValueComment":"P-value was obtained from 1-sided log rank test, stratified by ECOG PS, race group and brain metastases.","paramType":"Hazard Ratio (HR)","paramValue":"0.760","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not estimable due to the small number of participants who had event.","groupId":"OG000","lowerLimit":"45.8","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was not estimable due to the small number of participants who had event.","groupId":"OG001","lowerLimit":"32.2","upperLimit":"NA","value":"47.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"171"}],"units":"Participants"}],"description":"OS (in months) was defined as the duration from start of study treatment to date of death due to any cause. OS = (date of death minus the date of randomization of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The FA population included all participants who were randomized with study treatment assignment designated according to the initial randomization.","reportingStatus":"POSTED","timeFrame":"From randomization to death or last date known alive for those not known to have died (up to 72 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}